Day: February 3, 2022

Mrs. Sudnow brings data-driven retail perspective and increases diversity of thought on AFC Gamma’s expanded Board WEST PALM BEACH, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) — AFC Gamma, Inc. (NASDAQ:AFCG) (“AFC Gamma”) today announced the nomination and appointment of Marnie Sudnow to AFC Gamma’s Board of Directors. Mrs. Sudnow brings over 20 years of experience in executing digital advertising and e-commerce strategies for global retailers. In connection with the appointment of Mrs. Sudnow, the Board was expanded to eight directors, six of whom are independent. “Marnie is an accomplished business leader and her extensive experience in advertising and technology make her an ideal addition to AFC Gamma’s Board. Her distinct insights into the retail landscape bring unique and valuable insight on compelling investment opportunities within...

Fourth Quarter 2021 HighlightsTotal revenue of $3.7 billion, an increase of 6% with organic growth of 5% Operating margin of 22.7% as enterprise initiatives contributed 110 bps GAAP EPS of $1.93 including $(0.02) of MTS acquisition impactFull Year 2021 HighlightsTotal revenue of $14.5 billion, an increase of 15% with organic growth of 12% Operating income of $3.5 billion, an increase of 21% Operating margin of 24.1%, an increase of 120 bps as enterprise initiatives contributed 110 bps Record GAAP EPS of $8.51, an increase of 28%Full Year 2022 Guidance (including MTS)Total revenue growth of 7.5 to 10.5% with organic growth of 6 to 9% Operating margin of 24 to 25% with enterprise initiatives contributing 100 bps GAAP EPS of $8.90 to $9.30, an increase of 5 to 9% or 10 to 15% excluding 2021 one-time tax itemsGLENVIEW, Ill., Feb....

NEEDHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Francesca Barone, M.D., Ph.D., has been named as the company’s Chief Scientific Officer. Dr. Barone brings more than 20 years of experience in immunology, experimental medicine, and innovative drug development to help bring important new therapeutics to the clinic. Dr. Barone was previously Candel’s Vice President, Head of Research having joined the company in November 2020. Prior to Candel, Dr. Barone was Head of Experimental Medicine at Kintai Therapeutics and Senda Biosciences, two Flagship Pioneering companies. Before moving to industry, Dr. Barone was a Rheumatology Consultant and Associate Professor (Reader) at University...

Genasys’ Emergency Evacuation Planning and Alerting Resources Helping to Protect 1.4 Million Residents in Most Populous U.S. County SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the global leader in critical communications systems and solutions that help protect and keep people safe, today announced a multi-year Zonehaven software services and evacuation management contract with Los Angeles County. In addition to the 17 counties announced in October 2021 and last month, first responders, emergency services agencies, and 8.7 million residents in California now have access to Zonehaven’s critical evacuation planning, alerting, and real-time life safety resources. “Our unique and transformative Zonehaven software-as-a-service (SaaS) empowers first responders and emergency services agencies to...

NEW YORK, Feb. 03, 2022 (GLOBE NEWSWIRE) — Cowen Inc. (NASDAQ:COWN) (“Cowen” or the “Company”) today announced that Steven Mah, Ph.D., has joined the Company’s equity research team to further expand the firm’s coverage of the life science & diagnostic tools sector. He will be based in New York, and will report to Robert Fagin, Cowen’s Head of Research. “Cowen continues to build its market-leading life science & diagnostic tools franchise,” said Mr. Fagin. “Steve’s expertise in dynamic emerging market segments such as synthetic biology and artificial-intelligence driven health solutions will further differentiate our coverage.” Cowen’s acclaimed research department consists of 61 senior analysts covering over 975 securities across multiple sectors, including health care, consumer, energy, sustainability and energy transition,...

KING OF PRUSSIA, Pa., Feb. 03, 2022 (GLOBE NEWSWIRE) — Nocopi Technologies, Inc. (OTC Pink: NNUP), a developer of specialty reactive inks used in entertainment, toy and educational products as well as in document and product authentication technologies to combat fraud, today announced that it set its Annual Stockholders Meeting date for Thursday, June 16, 2022. The annual meeting date was announced in a Form 8-K filed on February 2, 2022. The Form 8-K also disclosed the Company’s adoption of Amended and Restated Bylaws, which reflect changes to certain aspects of the Company’s Board structure and governance guidelines. Nocopi’s SEC filings are available here, where you can view the Form 8-K and the Amended and Restated Bylaws in their entirety. Nocopi Chairman and CEO Michael Feinstein commented, “Nocopi has been transformed into...